FDA Probes Roche, Novartis Drugs' Link To Disorder

Law360, New York (April 11, 2008, 12:00 AM EDT) -- The U.S. Food and Drug Administration is investigating whether two drugs used to prevent organ rejection in transplant patients could lead to a rare and deadly nervous system disorder, the agency said Thursday.

The FDA is reviewing data from Roche Holding AG about instances of progressive multifocal leukoencephalopathy, or PML, in patients who have taken the company's transplant drug CellCept. The FDA has requested similar information on Novartis AG's drug Myfortic.

PML, caused by a virus that damages the nervous system, usually develops in patients who...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.